Sareum | Evaluate

August 14, 2020

Bristol hopes to Tyk the psoriasis box

The company’s massive clinical programme with BMS-986165 is set to deliver its first pivotal data later this year.

April 30, 2019

Lilly scraps two research assets, leaving few rivals behind

September 17, 2018

Tyk2 reaches tipping point

Bristol-Myers Squibb is ahead in a new oral class that could bring similar efficacy to current injectables for autoimmune diseases – but Pfizer seems less keen.

October 01, 2014

Therapy focus – Leukaemia opportunity gives FLT a chance to take flight

August 09, 2011

Bristol hopes to Tyk the psoriasis box

Lilly scraps two research assets, leaving few rivals behind

Tyk2 reaches tipping point

Therapy focus – Leukaemia opportunity gives FLT a chance to take flight

Therapeutic focus - Roche places big bet on novel chemotherapy enhancers

Latest Reports

JP Morgan 2022 Conference

PD(L)anner - December 2021

Editor's Picks

In 2021 it paid to stay private when the chips were down

Big beasts drive biopharma valuations higher in 2021

Another failure heaps more pressure on Novartis

Days of reckoning for immune checkpoint blockers

The bubble bursts for biotech stocks